Becker's Healthcare March 8, 2024
The FDA has approved Wegovy, Novo Nordisk’s version of semaglutide approved for weight loss, to be used to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight.
“Wegovy is now the first weight loss medication to also be approved to help prevent life-threatening cardiovascular events in adults with cardiovascular disease and either obesity or overweight,” John Sharretts, MD, director of the division of diabetes, lipid disorders and obesity in the FDA’s Center for Drug Evaluation and Research, said in a March 8 press release from the organization. “This patient population has a higher...
Today's Sponsors
Today's Sponsor